Washington Manual of Medical Therapeutics
Thrombocytosis
To view the entire topic, please sign in or purchase a subscription.
The Washington Manual of Medical Therapeutics helps you diagnose and treat hundreds of medical conditions. Consult clinical recommendations from a resource that has been trusted on the wards for 50+ years. Explore these free sample topics:
-- The first section of this topic is shown below --
General Principles
Definition
Thrombocytosis is defined as a platelet count of >450 × 10/L by the World Health Organization (WHO).
Etiology
Thrombocytosis has reactive and clonal etiologies that may coexist.
- Reactive thrombocytosis may occur during recovery from thrombocytopenia; after splenectomy; or in response to iron deficiency, acute infectious or chronic inflammatory states, trauma, and malignancies.
- Low risks of thrombosis or bleeding.
- Platelets normalize after improvement of the underlying disorder.
- If accompanied by thrombotic complications, evaluate for an underlying myeloproliferative disorder.
- Essential thrombocytosis (ET) is a chronic myeloproliferative disorder. Eventual progression to myelofibrosis, acute myeloid leukemia, or myelodysplastic syndrome occurs in a minority of ET patients.1
-- To view the remaining sections of this topic, please sign in or purchase a subscription --
General Principles
Definition
Thrombocytosis is defined as a platelet count of >450 × 10/L by the World Health Organization (WHO).
Etiology
Thrombocytosis has reactive and clonal etiologies that may coexist.
- Reactive thrombocytosis may occur during recovery from thrombocytopenia; after splenectomy; or in response to iron deficiency, acute infectious or chronic inflammatory states, trauma, and malignancies.
- Low risks of thrombosis or bleeding.
- Platelets normalize after improvement of the underlying disorder.
- If accompanied by thrombotic complications, evaluate for an underlying myeloproliferative disorder.
- Essential thrombocytosis (ET) is a chronic myeloproliferative disorder. Eventual progression to myelofibrosis, acute myeloid leukemia, or myelodysplastic syndrome occurs in a minority of ET patients.1
There's more to see -- the rest of this entry is available only to subscribers.
